Αποτελέσματα Αναζήτησης
This protocol is part of the AC-TH regimen: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Link to Breast adjuvant AC-TH overview; Link to Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly; Drug status: Docetaxel is on the PBS general schedule. Trastuzumab is PBS authority
This treatment regimen consists of two parts: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Breast neoadjuvant/adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly. Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly.
Results: In this study (N = 121), pCR was numerically higher with pertuzumab based regimens, including ddAC-THP (60%), TCHP (63%), THP (55%), as compared with ddAC-TH (46%). THP resulted in significantly less cycle delays due to toxicity compared to the other regimens (p=0.02).
26 Απρ 2016 · Adjuvant Regimen When an Anthracycline Is Not Preferred. Docetaxel plus cyclophosphamide (TC) × 4 is recommended as an alternative to AC × 4 and offers improved disease-free survival (DFS) and overall survival (OS). Classic CMF with oral cyclophosphamide for six cycles is another option.
1 Μαΐ 2018 · Dose-Dense AC + TH is usually given in an outpatient infusion center, allowing the person to go home afterwards. On occasion, it may be given in the hospital if someone is too sick. Dose-Dense AC is repeated every 2 weeks or 14 days.
G-CSF support (using standard or pegylated form) is required with all cycles of dose dense DOXOrubicin and cycloPHOSphamide. Facilities to treat anaphylaxis MUST be present when the systemic anti-cancer therapy (SACT) is administered.
8 Ιαν 2015 · The primary end point was survival free from invasive disease. Results. The median follow-up period was 4.0 years. The 3-year rate of survival free from invasive disease was 98.7% (95%...
